nejm glp 1 In the ACHIEVE-1 phase 3 trial, the oral small-molecule GLP-1 receptor agonist orforglipron significantly reduced the glycated hemoglobin level over a period of 40 weeks in adults with early type 2 diabetes Expanding Clinical Benefits for GLP-1–Receptor
Pay in 4 interest-free payments of $5.53 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9
























